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90.8%, and the success rate of the therapy with Imi-
penemfCilastatin was 71.4%.
RESULTS: Therapy with Tazobactam/Piperacillin re-
sulted in a total cost of DM 3,375 per successfully treated
patient. Therapy with ImipenemfCilastatin caused total
costs of DM 4,834 per successfully treated patient. Sensi-
tivity analyses were performed to prove the stability of
the results.
CONCLUSION: This cost-effectiveness analysis reveals
that a combination therapy with Tazobactam/Piperacillin
incurs lower total costs per successfully treated patient
than ImipenemfCilastatin.
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Several models of colorectal cancer (CRC) screening cost-
effectiveness have been published. Most of them are
based on US costs of parameters/tests used.
OBJECTIVE: The purpose of this analysis was to provide
a model to compare several screening programs using
cost data related on Italian reimbursement system, both
for ambulatorial and for hospital services.
METHODS: Four screening programs were assessed in
comparison with nonscreening: annual fecal occult blood
test alone (FOBT), flexible sigmoidoscopy every five
years (FS), FOBT and FS combined, and one-time colono-
scopy (CO). The analysis was carried out by considering
a 10-year screening period. Effectiveness data were de-
rived from recent literature; cost-effectiveness was de-
fined as "cost per cancer prevented" (CCP) and "cost per
cancer death prevented" (CCDP). Computer analysis was
performed using algebraic formula. Data robustness was
tested with sensitivity analysis of main variables: patient
compliance, cost of cancer care, and cost of CO compli-
cation. Maximization analysis was carried out on a risk
population (selected screening).
RESULTS: CO had the greatest impact on CRC mortal-
ity, followed by FS+FOBT, FS, and FOBT. CO also re-
sulted in the most cost-effective program, both for CCP
and for CCDP, followed by FOBT+ FS, FS, and FOBT for
all the compliance levels considered. Sensitivity analysis
reinforced these results. Maximization analysis amplified
both efficacy and cost-effectiveness of CO as a test for se-
lected screening.
CONCLUSION: This model, even with the limitation
linked to cost assumption problems, seems to be useful
for authorities that will organize general population CRC
screening programs.
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OBJECTIVE: The purpose of this study was to achieve a
cost-effectiveness analysis of the alternative piperacillin-
tazobactam (PTZ) versus ceftazidime (CFZ) both used in
conjunction with amikacin, as a therapy in post-chemo-
therapy febrile neutropenia.
METHODS: Efficacy data were obtained from the two
clinical trials performed by the European Organization
for Research and Treatment of Cancer (EORTC) and the
Groupe detudc des Aplasies Febriles (GAF). A cost-effec-
tiveness analysis has been carried out using the software
Multiprograma DUE-Estudios Farmacoeconomicos. It has
considered the alternatives (PTZ and CFZ), the type of
pharmacoeconomical study (cost-effectiveness analysis),
the pathology (febrile neutropenia), the perspective of the
study (hospital), the number of patients (493 and 498, re-
spectively), and the type of case (dependent). The follow-
ing costs have been imputed to each one of the branches
of the tree decision according to the software: the acquisi-
tion cost, the preparation and administration cost, the
monitoring cost, the treatment of adverse effects, the
structural cost, and the cost of therapeutic failure.
RESULTS: The cost per unit of effectiveness was $5,250
with PTZ and $5,850 with CFZ. The incremental cost
was $1,472 per additional case prevented with PTZ in-
stead of CFZ. The sensitivity analysis carried out regard-
ing the variables: the percentage of success, the percent-
age of overinfections, and the price of the pharmaceutical
product verified the first results of the cost-effectiveness
analysis.
CONCLUSIONS: The alternative PTZ presented a better
cost-effectiveness relation to the CFZ in the treatment of
the fever and bacteriemia in neutropenic patients, offer-
ing a reduction of the cost per unit of treatment success-
ful of $635.
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OBJECTIVE: To compare the efficiency of piperacillin-
tazobactam (Pip-Taz) and imipenern-cilasratin (Imi-Cil)
in the treatment of intra-abdominal infections, through a
cost-effectiveness analysis.
METHODS: A decision analytic model was developed to
compare the costs and outcomes of both regimens. The ef-
